RB1 and breast carcinoma: All of these proteins have the ability to activate the E2F-pRb pathway and induce the proliferation of breast cancer cells [30,31,32] As a result, only ribociclib and abemaciclib, given at clinically relevant doses, showed the same efficacy against cancer cells grown in the bone tumor microenvironment and as a monocolture.